Teva Pharmaceutical Industries has decided not to pursue development of laquinimod, and has returned rights to the drug back to Swedish group Active Biotech. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/teva_drops_development_of_laquinimod_1251494Takeda has revealed that it is considering making a move on Shire to add ballast to its core therapeutic areas. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/takeda_eyes_up_shire_1229776Eli Lilly is teaming up with Anima Biotech in an exclusive collaboration to discover and develop translation inhibitors for several protein targets. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/lilly_links_with_anima_1245496Pharmaceutical companies “are doing everything in their power” to minimise disruption to the supply of medicines should the UK leave the EU under a ‘no-deal’ scenario, but a deal is urgently needed to fully protect patients, MPs have been told. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/abpi_tells_mps_brexit_deal_on_medicines_regulation_urgently_needed_1255350Takeda says it has received unconditional clearance from the US Federal Trade Commission for the proposed acquisition of Shire. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/takeda_gets_us_nod_for_shire_buy_1243748Novartis’ generics arm Sandoz has launched the second Healthcare Access Challenge (HACk), which is looking to support digital solutions to local healthcare access challenges. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/sandoz_launches_second_digital_health_competition_1254475The US Food and Drug Administration has rejected Valeant group Ortho Dermatologics’ plaque psoriasis therapy Duobrii. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/us_regulators_reject_valeants_duobrii_1240725US regulators have approved Paratek’s Seysara for the treatment of acne in patients aged nine years or older. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/green_light_for_acne_drug_seysara_in_the_us_1254328Bausch Health group Ortho Dermatologics has resubmitted an application to market its plaque psoriasis lotion Duobrii in the US - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/ortho_resubmits_duobrii_in_the_us_1249157AcelRx' Dzuveo has won approval in the European Unionl for the management of acute moderate to severe pain in medically monitored settings. - News - PharmaTimes
by Selina McKee
www.pharmatimes.com/news/eu_approval_for_acelrx_dzuveo_1242324
